Indegene Ltd (INDGN) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management reaffirmed its target to reach quarterly EBITDA margins of 19%-plus by Q4 FY27, expecting margin growth to outpace revenue growth in H2.
- The integration of the BioPharm acquisition has yielded $1.5 million in cost savings and is now providing a data-driven competitive edge in new business pursuits.
- A large $10 million ACV outcome-based contract will see its most significant revenue and margin contribution recognized in Q4 FY27, underpinning confidence in a strong finish.
Performance Overview
- The company reported five consecutive quarters of over 5% QoQ revenue growth in INR terms, driven by balanced expansion across its client base.
- Strong growth was observed in key client accounts, with top five clients growing 9.2% and top 20 clients growing 6.7% sequentially in INR.
- The client base expanded to 107 active clients, with a notable increase in clients contributing over $1 million annually to 59, up from 54 last quarter.
- Productivity increased, with revenue per employee on a trailing 12-month basis rising to USD 79,600 from USD 69,000 a year ago, attributed to GenAI platforms and output-based pricing.
- The company secured nine new deals with annual contract values of about $1 million each, including one large deal in the $5 million-plus range.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.